Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on the safety, tolerability, pharmacokinetics, and pharmacodynamics of long-term mitapivat dosing in adults with stable sickl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemolytic Anemia
• Sickle Cell Disease

Drugs mentioned

• Mitapivat (Pyrukynd) (mitapivat)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Sickle Cell Disease, Hemolytic Anemia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING